RBC Capital analyst Shagun Singh raised the firm’s price target on Insulet (PODD) to $380 from $370 and keeps an Outperform rating on the shares after the company’s Investor Day presentation. The firm comes away from the event more bullish on Insulet’s future prospects, including growth runway and market leadership in a highly under-penetrated end-market, the analyst tells investors in a research note. RBC is also raising its FY26 EPS view to $6.28 from $5.99 and its FY27 view to $8.03 from $7.27.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $380 from $370 at BTIG
- Insulet’s Promising Growth Potential: A Buy Rating Despite Market Skepticism
- Insulet’s Ambitious Growth Targets and Strategic Initiatives Reinforce Buy Rating with Revised Price Target of $380
- Insulet’s Strategic Growth and Innovation Drive ‘Buy’ Rating with $360 Price Target
- Insulet’s Promising Growth: Buy Rating Backed by Strong Sales Projections and Innovation Investment